The topical study of inhaled drug (salbutamol) delivery in idiopathic pulmonary fibrosis
Omar S Usmani, Martyn F Biddiscombe, Shuying Yang, Sally Meah, Eunice Oballa, Juliet K Simpson, William A Fahy, Richard P Marshall, Pauline T Lukey, Toby M Maher, Omar S Usmani, Martyn F Biddiscombe, Shuying Yang, Sally Meah, Eunice Oballa, Juliet K Simpson, William A Fahy, Richard P Marshall, Pauline T Lukey, Toby M Maher
Abstract
Background: Our aim was to investigate total and regional lung delivery of salbutamol in subjects with idiopathic pulmonary fibrosis (IPF).
Methods: The TOPICAL study was a 4-period, partially-randomised, controlled, crossover study to investigate four aerosolised approaches in IPF subjects. Nine subjects were randomised to receive 99mTechnetium-labelled monodisperse salbutamol (1.5 μm or 6 μm; periods 1 and 2). Subjects also received radio-labelled salbutamol using a polydisperse nebuliser (period 3) and unlabelled salbutamol (400 μg) using a polydisperse pressurized metered dose inhaler with volumatic spacer (pMDI; period 4).
Results: Small monodisperse particles (1.5 μm) achieved significantly better total lung deposition (TLD, mean % ± SD) than larger particles (6 μm), where polydisperse nebulisation was poor; (TLD, 64.93 ± 10.72; 50.46 ± 17.04; 8.19 ± 7.72, respectively). Small monodisperse particles (1.5 μm) achieved significantly better lung penetration (mean % ± SD) than larger particles (6 μm), and polydisperse nebulisation showed lung penetration similar to the small particles; PI (mean ± SD) 0.8 ± 0.16, 0.49 ± 0.21, and 0.73 ± 0.19, respectively. Higher dose-normalised plasma salbutamol levels were observed following monodisperse 1.5 μm and 6 μm particles, compared to polydisperse pMDI inhalation, while lowest plasma levels were observed following polydisperse nebulisation.
Conclusion: Our data is the first systematic investigation of inhaled drug delivery in fibrotic lung disease. We provide evidence that inhaled drugs can be optimised to reach the peripheral areas of the lung where active scarring occurs in IPF.
Trial registration: This trial was registered on clinicaltrials.gov ( NCT01457261 ).
Keywords: Gamma scintigraphy; Idiopathic pulmonary fibrosis (IPF); Inhaled drug delivery.
Conflict of interest statement
Ethics approval and consent to participateThe study was approved by the London-Chelsea research ethics committee (11/LO/0372). All subjects provided signed informed consent.
Consent for publicationThe institutional consent form was used to cover publication of individual images.
Competing interestsTMM has received industry-academic funding from GlaxoSmithKline R&D, UCB and Novartis and has received consultancy or speaker’s fees from Apellis, Astra Zeneca, aTyr pharma, Bayer, Biogen Idec, Boehringer Ingelheim, Cipla, GlaxoSmithKline R&D, InterMune, ProMetic, Roche, Sanofi-Aventis, and UCB. OSU has received industry-academic funding from Boehringer Ingelheim, Chiesi, Edmond Pharma, GlaxoSmithKline, Mundipharma International, and has received consultancy or speaker fees from Astra Zeneca, Boehringer Ingelheim, Chiesi, Cipla, Edmond Pharma, GlaxoSmithKline, Napp, Novartis, Mundipharma International, Pearl Therapeutics, Roche, Sandoz, Takeda, UCB, Vectura and Zentiva. MFB has received industry-academic funding from Boehringer Ingelheim, Chiesi, and GlaxoSmithKline. PTL, RPM, SY, JKS, EO and WAF are employees and shareholders of GlaxoSmithKline R&D.
Publisher’s NoteSpringer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figures
References
- Arbat S, et al. Study of factors affecting mortality in ILD cases over 2 years. Eur Respir J. 2016;48(suppl 60)
- Hutchinson J, et al. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J. 2015;46(3):795–806. doi: 10.1183/09031936.00185114.
- Kärkkäinen M, et al. Course of disease and cause of death in patients with idiopathic pulmonary fibrosis in eastern Finland. Eur Respir J. 2015;46(suppl 59)
- Rogliani P, et al. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Pulm Pharmacol Ther. 2016;40:95–103. doi: 10.1016/j.pupt.2016.07.009.
- Lavorini F, Fontana GA, Usmani OS. New inhaler devices-the good, the bad and the ugly. Respiration. 2014;88(1):3–15. doi: 10.1159/000363390.
- Okuda R, et al. Efficacy and safety of inhaled N-acetylcysteine in idiopathic pulmonary fibrosis: a prospective, single-arm study. Respir Investig. 2016;54(3):156–161. doi: 10.1016/j.resinv.2015.10.001.
- Fusiak T, Smaldone GC, Condos R. Pulmonary fibrosis treated with inhaled interferon-gamma (IFN-γ) J Aerosol Med Pulm Drug Deliv. 2015;28(5):406–410. doi: 10.1089/jamp.2015.1221.
- Markart P, et al. Safety and tolerability of inhaled heparin in idiopathic pulmonary fibrosis. J Aerosol Med Pulm Drug Deliv. 2010;23(3):161–172. doi: 10.1089/jamp.2009.0780.
- Strickland NH, et al. Cause of regional ventilation-perfusion mismatching in patients with idiopathic pulmonary fibrosis: a combined CT and scintigraphic study. AJR Am J Roentgenol. 1993;161(4):719–725. doi: 10.2214/ajr.161.4.8372745.
- Ogawa Y, et al. Regional ventilation-perfusion mismatch in interstitial pneumonia correlation between scintigraphy and CT. Clin Nucl Med. 1997;22(3):166–171. doi: 10.1097/00003072-199703000-00006.
- Suga K, et al. Characteristic crescentic subpleural lung zones with high ventilation (V)/perfusion (Q) ratios in interstitial pneumonia on V/Q quotient SPECT. Nucl Med Commun. 2009;30(11):881–889. doi: 10.1097/MNM.0b013e328330571d.
- Hirani N, et al. TD139, A Novel Inhaled Galectin-3 Inhibitor for The Treatment of Idiopathic Pulmonary Fibrosis (IPF). Results from The First in (IPF) Patients Study. QJM. 2016;109(suppl_1):S16-S16.
- Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of β2-agonist particle size. Am J Respir Crit Care Med. 2005;172(12):1497–1504. doi: 10.1164/rccm.200410-1414OC.
- Hindle M, Chrystyn H. Determination of the relative bioavailability of salbutamol to the lung following inhalation [see comments] Br J Clin Pharmacol. 1992;34(4):311–315. doi: 10.1111/j.1365-2125.1992.tb05921.x.
- Hindle M, Newton D, Chrystyn H. Investigations of an optimal inhaler technique with the use of urinary salbutamol excretion as a measure of relative bioavailability to the lung. Thorax. 1993;48(6):607–610. doi: 10.1136/thx.48.6.607.
- Raghu G, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824. doi: 10.1164/rccm.2009-040GL.
- Assayag D, et al. The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis. Respir Med. 2015;109(8):1058–1062. doi: 10.1016/j.rmed.2015.06.012.
- Usmani OS, et al. Characterization of the generation of radiolabeled monodisperse albuterol particles using the spinning-top aerosol generator. J Nucl Med. 2004;45(1):69–73.
- Biddiscombe MF, Usmani OS, Barnes PJ. A system for the production and delivery of monodisperse salbutamol aerosols to the lungs. Int J Pharm. 2003;254(2):243–253. doi: 10.1016/S0378-5173(03)00032-2.
- Newman S, et al. Standardization of techniques for using planar (2D) imaging for aerosol deposition assessment of orally inhaled products. J Aerosol Med Pulm Drug Deliv. 2012;25(S1):S-10–S-28. doi: 10.1089/jamp.2012.1Su4.
- Du X-L, et al. Pharmacokinetics and relative bioavailability of salbutamol metered-dose inhaler in healthy volunteers. Acta Pharmacol Sin. 2002;23(7):663–666.
- Elers J, et al. Blood and urinary concentrations of salbutamol in asthmatic subjects. Med Sci Sports Exerc. 2010;42(2):244–249. doi: 10.1249/MSS.0b013e3181b2e87d.
- Horan GS, et al. Partial inhibition of integrin αvβ6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med. 2008;177(1):56–65. doi: 10.1164/rccm.200706-805OC.
- Lipson KE, et al. CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. Fibrogenesis Tissue Repair. 2012;5(1):1. doi: 10.1186/1755-1536-5-1.
- Edwards CD, et al. Development of a novel quantitative structure-activity relationship model to accurately predict pulmonary absorption and replace routine use of the isolated perfused respiring rat lung model. Pharm Res. 2016;33(11):2604–2616. doi: 10.1007/s11095-016-1983-4.
- Bäckman P, et al. Advances in inhaled technologies: understanding the therapeutic challenge, predicting clinical performance, and designing the optimal inhaled product. Clin Pharmacol Therap. 2014;95(5):509–520. doi: 10.1038/clpt.2014.27.
- Patton JS, et al. The particle has landed--characterizing the fate of inhaled pharmaceuticals. J Aerosol Med Pulm Drug Deliv. 2010;23(Suppl 2):S71–S87.
- Cottin V, Maher T. Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis. Eur Respir Rev. 2015;24(135):58–64. doi: 10.1183/09059180.00011514.
- Biddiscombe MF, et al. Comparing lung regions of interest in gamma scintigraphy for assessing inhaled therapeutic aerosol deposition. J Aerosol Med Pulm Drug Deliv. 2011;24(3):165–173. doi: 10.1089/jamp.2010.0845.
- Mukhopadhyay S, et al. The quantitative distribution of nebulized antibiotic in the lung in cystic fibrosis. Respir Med. 1994;88(3):203–211. doi: 10.1016/S0954-6111(05)80348-8.
- Fairfax A, et al. Pulmonary disorders associated with Sjögren’s syndrome. QJM. 1981;50(3):279–295.
- Bando M, et al. Long-term efficacy of inhaled N-acetylcysteine in patients with idiopathic pulmonary fibrosis. Intern Med. 2010;49(21):2289–2296. doi: 10.2169/internalmedicine.49.4011.
- Homma S, et al. Efficacy of inhaled N-acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis. Respirology. 2012;17(3):467–477. doi: 10.1111/j.1440-1843.2012.02132.x.
- Muramatsu Y, et al. Effect of inhaled N-acetylcysteine monotherapy on lung function and redox balance in idiopathic pulmonary fibrosis. Respir Investig. 2016;54(3):170–178. doi: 10.1016/j.resinv.2015.11.004.
- Diaz KT, et al. Delivery and safety of inhaled interferon-gamma in idiopathic pulmonary fibrosis. J Aerosol Med Pulm Drug Deliv. 2012;25(2):79–87. doi: 10.1089/jamp.2011.0919.
- Skaria SD, et al. Inhaled interferon and diffusion capacity in idiopathic pulmonary fibrosis (IPF) Sarcoidosis Vasc Diffuse Lung Dis. 2015;32(1):37–42.
- Hochhaus G, Möllmann H. Pharmacokinetic/pharmacodynamic characteristics of the beta-2-agonists terbutaline, salbutamol and fenoterol. Int J Clin Pharmacol Ther Toxicol. 1992;30(9):342–362.
- Newman SP, et al. Deposition of pressurised aerosols in the human respiratory tract. Thorax. 1981;36(1):52–55. doi: 10.1136/thx.36.1.52.
- Hindle M, Chrystyn H. Relative bioavailability of salbutamol to the lung following inhalation using metered dose inhalation methods and spacer devices. Thorax. 1994;49(6):549–553. doi: 10.1136/thx.49.6.549.
- Hindle M, et al. Relative bioavailability of salbutamol to the lung following inhalation via a novel dry powder inhaler and a standard metered dose inhaler. Br J Clin Pharmacol. 1997;43(3):336–338. doi: 10.1046/j.1365-2125.1997.00564.x.
- Chege J, Chrystyn H. Volumatic usage: some generic salbutamol metered dose inhalers can be used. Thorax. 1994;49(11):1162–1163. doi: 10.1136/thx.49.11.1162.
- Silkstone V, et al. Relative bioavailability of salbutamol to the lung following inhalation when administration is prolonged. Br J Clin Pharmacol. 2000;50(3):281–284. doi: 10.1046/j.1365-2125.2000.00255.x.
Source: PubMed